MedMira Launches Rapid HIV Test into Retail OTC Market

MedMira Launches Rapid HIV Test into Retail OTC Market
Ships New MiraCare(TM) OTC Product to Retail Pharmacies 


HONG KONG, Jan. 24  /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow- through
diagnostic technology, today announced the launch of its MiraCare(TM) HIV Rapid
Antibody Test, its first Over-The-Counter (OTC) test, into the global
marketplace, starting with Hong Kong and Macao, People's Republic of China.
MiraCare(TM) will be distributed to pharmacies in these regions by Goodman
Medical Supplies Ltd., a well-established medical supply distributor.
MiraCare(TM) became available in pharmacies today.

This new finger-stick whole blood rapid HIV test is built on MedMira's proven,
unique platform used in its market-leading MiraWell(TM) and Reveal(TM) product
lines. Each MiraCare(TM) test is sold as a complete test package with all
components required for an individual to conduct the test quickly; with results
showing in just three minutes.

"Launching this new product line into the OTC market is a pivotal moment in
MedMira's history," said Stephen Sham, Chairman and Chief Executive Officer of
MedMira Inc. "The introduction of our new MiraCare(TM) line of rapid tests into
point-of-testing settings will serve as a model for future expansion of this
product into OTC markets in China, the rest of Asia, and ultimately around the
world as these markets become more prepared for an OTC rapid HIV test."

Sham continued, "With almost 40 years of experience, Goodman Medical Supplies
Ltd. is the ideal partner to join MedMira in opening this Hong Kong and Macao
market through its experienced sales force and extensive knowledge and networks
in these regions."

Collen Chan, Managing Director of Goodman Medical Supplies Ltd. said, "Over the
past year, we have dedicated substantial resources to identifying the
best-suited rapid HIV test for our retail pharmacy sector. Of the rapid HIV
tests available in China, MedMira was the only manufacturer that could deliver
a quality product with a simple test procedure and a truly rapid and accurate
test result in less than three minutes."

Chan continued, "In addition, the fact that the recent China Centres for
Disease Control (CDC) evaluation proved MedMira's test to be number one, and
that MedMira is the only rapid HIV test manufacturer to hold regulatory
approvals in China, the United States and Canada shows us that we have
identified the best company and product for our OTC market."

About Goodman Medical

Goodman Medical Supplies Ltd. ("Goodman Medical") was established in 1966 and
is one of the pioneers of medical suppliers in the healthcare market of Hong
Kong. It offers a variety of medical products for hospital, community and
personal care. Goodman Medical prides itself with a goal of sharpening
competitiveness to meet the rapidly changing challenges of the healthcare
market, and to serve customers with the highest value of service. It sets its
quality standards high, and as a result, distributes only the highest caliber
of medical products. Over the years, Goodman Medical has established itself to
be the partner of choice for healthcare services. Further information about
Goodman Medical Supplies Ltd. is available on its website:

  http://www.goodmanmedical.org/

  About MedMira



MedMira is the leading global manufacturer and marketer of in vitro flow-though
rapid diagnostic tests for the clinical laboratory market. MedMira's tests
provide reliable, rapid diagnosis in just 3 minutes for the detection of human
antibodies in human serum, plasma or whole blood for diseases such as HIV. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For
more information visit MedMira's website at http://www.medmira.com/.

MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in
clinical laboratories and hospitals where professional counseling and patient
treatment are immediately available.

MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada with a representative
office in Beijing, China.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement. 

DATASOURCE: MedMira Inc.



CONTACT: Media Contact: Investor Relations: Dr. James Smith:

[phone] or e-mail: 

Copyright